Boston Scientific Co. (NYSE:BSX) Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. decreased its holdings in Boston Scientific Co. (NYSE:BSX) by 6.9% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 113,303 shares of the medical equipment provider’s stock after selling 8,450 shares during the period. Pacer Advisors Inc.’s holdings in Boston Scientific were worth $9,495,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Triad Wealth Partners LLC acquired a new position in Boston Scientific during the second quarter worth approximately $26,000. Values First Advisors Inc. purchased a new stake in shares of Boston Scientific during the 3rd quarter valued at $28,000. E Fund Management Hong Kong Co. Ltd. acquired a new stake in shares of Boston Scientific during the 3rd quarter worth $30,000. Capital Performance Advisors LLP purchased a new position in shares of Boston Scientific in the 3rd quarter worth $30,000. Finally, Andra AP fonden acquired a new position in Boston Scientific in the second quarter valued at $29,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on BSX. BTIG Research raised their price objective on Boston Scientific from $84.00 to $93.00 and gave the stock a “buy” rating in a report on Monday, October 14th. StockNews.com cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. Citigroup increased their price objective on shares of Boston Scientific from $92.00 to $98.00 and gave the stock a “buy” rating in a research report on Thursday, October 24th. Bank of America lifted their target price on shares of Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. Finally, Sanford C. Bernstein increased their price target on Boston Scientific from $92.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $93.39.

Boston Scientific Stock Down 1.6 %

NYSE:BSX opened at $90.00 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. The company has a market capitalization of $132.64 billion, a price-to-earnings ratio of 74.38, a price-to-earnings-growth ratio of 2.69 and a beta of 0.79. Boston Scientific Co. has a one year low of $53.93 and a one year high of $91.93. The stock has a 50-day simple moving average of $85.99 and a 200 day simple moving average of $80.16.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, topping the consensus estimate of $0.59 by $0.04. The company had revenue of $4.21 billion during the quarter, compared to analyst estimates of $4.04 billion. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The business’s revenue was up 19.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.50 EPS. Sell-side analysts predict that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In related news, Director Edward J. Ludwig sold 4,877 shares of the business’s stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $91.63, for a total transaction of $446,879.51. Following the completion of the sale, the director now owns 39,398 shares of the company’s stock, valued at $3,610,038.74. This represents a 11.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael F. Mahoney sold 162,777 shares of Boston Scientific stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $84.63, for a total value of $13,775,817.51. Following the completion of the transaction, the chief executive officer now owns 1,572,096 shares of the company’s stock, valued at approximately $133,046,484.48. The trade was a 9.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 314,147 shares of company stock worth $26,643,598 over the last 90 days. Insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.